CAPRICOR THERAPEUTICS SHARES FALL 60% PREMARKET AFTER FDA STAFF REVIEW SAYS DATA FOR CO'S DUCHENNE CELL THERAPY DOES NOT PROVIDE SUBSTANTIAL EVIDENCE OF EFFECTIVENESS

Reuters · 2d ago

Please log in to view news